Cytrx Corporation

Epimmune Inc.

Genimmune N.v.

Other

Pharmexa Inc.

Mark Joseph Newman

R Martin Emanuele

Mannarsamy Balasubramanian

Charles William Todd

Robert Newton Brey, Iii

Carlos A Rivera-Marrero

Alessandro D Sette

Robert W Chesnut

Brian D Livingston

Jeffery L Alexander

Scott Douglas Power

Lilia Maria Babe

Scott Southwood

Yiyou Chen

Lawrence M Deyoung

Manley T F Huang

Konstantin G Kousoulas

Hameedsulthan S Allaudeen

Denise Marie Baker

Pamuk A Bilsel

R Martin Emanuel

Florence Dal Degan

The present invention provides novel artificial oligopeptides capable of binding HLA Class II molecules encoded by several alleles. The oligopeptides include the sequence AXFVAAXTLXAXA (SEQ ID NO:1), wherein Xis H; Xis selected from the group consisting of F, N, Y and W; Xis H and Xis selected from the group consisting of A, D and E. The invention also relates to large peptides comprising the oligopeptides, polynucleotides encoding the oligopeptides and larger peptides, as well as to compositions comprising the oligopeptides, peptides or polynucleotides. Also disclosed are methods for inducing immune responses.

PAN-DR binding polypeptides and uses thereof

The present invention provides polynucleotides and polypeptides capable of enhancing the immune response of a human in need of protection against influenza virus infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an influenza protein or a fragment, variant, or derivative thereof, or at least one polypeptide encoded therefrom. The present invention also relates to identifying and preparing influenza virus epitopes and to polynucleotides and polypeptides comprising such influenza virus epitopes. The present invention also relates to compositions and methods of use in the prevention and treatment of influenza virus infection.

Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions

The present invention provides novel artificial oligopeptides capable of binding HLA Class II molecules encoded by several alleles. The oligopeptides include the sequence AXFVAAXTLXAXA (SEQ ID NO:1), wherein Xis selected from the group consisting of W, F, Y, H, D, E, N, Q, I and K; Xis selected from the group consisting of F, N, Y and W; Xis selected from the group consisting of H and K, and Xis selected from the group consisting of A, D and E, with the proviso that the oligopeptide sequence is not AKFVAAWTLKAAA. The invention also relates to larger peptides comprising the oligopeptides, polynucleotides encoding the oligopeptides and larger peptides, as well as to compositions comprising the oligopeptides, peptides or polynucleotides. Also disclosed are methods for inducing immune responses.

Pan-DR binding polypeptides and uses thereof

The invention relates to the field of biology. In particular, it relates to multi-epitope nucleic acid and peptide vaccines and methods of designing such vaccines to provide increased immunogenicity.

Optimized multi-epitope constructs and uses thereof

The invention relates to the field of biology. In particular, the invention relates to a method and system for designing optimized multi-epitope vaccines having selected combinations of amino acid insertions at the junctions of the multi-epitope constructs so as to minimize the number of junctional epitopes and provide vaccines with increased immunogenicity.

Method and system for optimizing minigenes and peptides encoded thereby

The present invention comprises novel polyoxyethylene/polyoxypropylene block copolymers compositions and compounds. The compositions comprise block copolymers that are useful in gene therapy methods.

Adjuvants and copolymer compositions

The present invention relates to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences. In particular, compositions and methods using biologically active nononic reverse block copolymers are described. The reverse copolymers have an inner core of polyoxyethylene (POE) that is flanked on either end by polyoxpropylene (POP). The reverse block copolymers have the following formula:wherein 'b' represents a number such that the molecular weight of the hydrophobe (CHO)is between approximately 750 and 20,000 Daltons and 'a' represents a number such that the percentage of hydrophile (CHO)is between approximately 1% and 90% of the weight of the block copolymer.

Therapeutic delivery compositions and methods of use thereof

The present invention comprises novel polyoxyethylene/polyoxypropylene block copolymer compositions and compounds. The compositions comprise block copolymers that are high molecular weight molecules, and are useful in gene therapy methods.

The present invention includes novel polyoxyethylene/polyoxypropylene block copolymers as well as methods for making the block copolymers. The block copolymers are high molecular weight molecules and are useful as general surfactants and display enhanced biological efficacy as vaccine adjuvants.

Vaccine adjuvant and vaccine method

Vaccine adjuvant and vaccine

Growing community of inventors

Duluth, GA, United States of America

Mark Joseph Newman